Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6282483rdf:typepubmed:Citationlld:pubmed
pubmed-article:6282483lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:6282483lifeskim:mentionsumls-concept:C0205696lld:lifeskim
pubmed-article:6282483lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:6282483lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:6282483lifeskim:mentionsumls-concept:C0042679lld:lifeskim
pubmed-article:6282483lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:6282483pubmed:issue2-3lld:pubmed
pubmed-article:6282483pubmed:dateCreated1982-8-26lld:pubmed
pubmed-article:6282483pubmed:abstractTextTwelve patients with small-cell anaplastic carcinoma of the lung were treated with vincristine 1 mg/m2 i.v. day 1, adriamycin 50 mg/M2 i.v. day 1, cyclophosphamide 1,000 mg/m2 i.v. day 1, and etoposide 80 mg/m2 i.v. day 2, 4, 6 given on an outpatient basis and repeated at 3-week intervals. As consolidation therapy seven patients received two courses of BCNU median 29 mg/m2 (range 24-73 mg/m2) short term intraarterial infusion in the bronchial artery with 2 to 3-weeks intervals. One patient with limited disease had no evidence of disease for 13+ months and one patient complete remission for 3+ months. Four of ten patients with extensive disease had complete remission for median 5 months (range 2+ to 5+ months) and four patients had partial remission for median 5 months (range 4 to 5+ months). Despite side effects the chemotherapy was well tolerated by the patients. The results correspond to those obtained with other effective regimens in small-cell anaplastic carcinoma of the lung.lld:pubmed
pubmed-article:6282483pubmed:languageenglld:pubmed
pubmed-article:6282483pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6282483pubmed:citationSubsetIMlld:pubmed
pubmed-article:6282483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6282483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6282483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6282483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6282483pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6282483pubmed:statusMEDLINElld:pubmed
pubmed-article:6282483pubmed:issn0344-5704lld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:JonssonKKlld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:MattssonWWlld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:HellekantCClld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:ArwidiAAlld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:von EybenF...lld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:LindahlS ASAlld:pubmed
pubmed-article:6282483pubmed:authorpubmed-author:TennvallLLlld:pubmed
pubmed-article:6282483pubmed:issnTypePrintlld:pubmed
pubmed-article:6282483pubmed:volume7lld:pubmed
pubmed-article:6282483pubmed:ownerNLMlld:pubmed
pubmed-article:6282483pubmed:authorsCompleteYlld:pubmed
pubmed-article:6282483pubmed:pagination195-7lld:pubmed
pubmed-article:6282483pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:meshHeadingpubmed-meshheading:6282483-...lld:pubmed
pubmed-article:6282483pubmed:year1982lld:pubmed
pubmed-article:6282483pubmed:articleTitleVincristine, Adriamycin, cyclophosphamide, and etoposide (VP16-213) in small-cell anaplastic carcinoma of the lung.lld:pubmed
pubmed-article:6282483pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6282483lld:pubmed